Grantham, Mayo, Van Otterloo & Co (GMO)
GHDX

Grantham, Mayo, Van Otterloo & Co (GMO)’s Genomic Health, Inc. GHDX Stock Holding History

Grantham, Mayo, Van Otterloo & Co (GMO)’s Portfolio GHDX Stock Details GHDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-4,800
Closed -$336K – 808
2019
Q1 		$336K Hold
4,800
– – ﹤0.01% 624
2018
Q4 		$309K Buy
+4,800
New +$336K ﹤0.01% 482

Other funds holding GHDX

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Grantham, Mayo, Van Otterloo & Co (GMO)'s GHDX Position: Q2 2019 in Review

Grantham, Mayo, Van Otterloo & Co (GMO) sold out of Genomic Health, Inc. (GHDX) in Q2 2019, closing a stake of 4,800 shares — an estimated $336K sold.

Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in GHDX in Q4 2018 and held it in 2 quarters. The position peaked at $336K in Q1 2019. 215 funds tracked by Wall St. Rank hold GHDX as of Q2 2019.

  • Grantham, Mayo, Van Otterloo & Co (GMO) reported no remaining Genomic Health, Inc. position as of Q2 2019 after selling out during the quarter.
  • Grantham, Mayo, Van Otterloo & Co (GMO) sold 4,800 Genomic Health, Inc. shares in Q2 2019, an estimated $336K.
  • Grantham, Mayo, Van Otterloo & Co (GMO) first reported a position in Genomic Health, Inc. in Q4 2018 and held it in 2 quarters.
  • Grantham, Mayo, Van Otterloo & Co (GMO)'s Genomic Health, Inc. position peaked at $336K in Q1 2019.
  • 215 funds tracked by Wall St. Rank held Genomic Health, Inc. as of Q2 2019.

Based on Grantham, Mayo, Van Otterloo & Co (GMO)'s 13F filing for Q2 2019, filed 13 Aug 2019.